[ad_1]
by E.j. Mundell, Healthday Reporter
New studies show that the administration of an "exposure patch" via a patch to help reduce peanut allergy in children is quite effective, but not as effective as l & # 39; Administration of minute amounts of peanuts through the mouth.
The international trial involved 356 children aged 4 to 11, from five countries. All had been diagnosed with allergy to peanut and had to wear either a skin patch containing a very small amount of peanut allergen (250 micrograms), or an allergen free placebo patch.
They were then tested with a "peanut challenge", in which a child is gradually fed with a growing (but still minute) dose of peanuts, ranging from 1 milligram to 300 milligrams.
The result: about a third of the children who wore the patch (35.3%) seemed to have benefited from it, the response to the challenge of peanut having decreased. This was true for only 13.6% of children who had worn the placebo patch, according to a team led by Dr. David Fleischer of the Colorado Children's Hospital in Aurora.
Yet this means that the peanut allergy patch has do not help two-thirds of the children who used it.
And for ethical reasons, children with severe peanut allergies who had had a life-threatening reaction – and who could make the most of the treatment – were not included in the new test.
An allergist who did not participate in the study thinks there may be more changes to the therapy.
"This study confirms the effectiveness of the peanut patch in the treatment of peanut allergy, but the response rate is not as robust as expected," said Dr. Punita Ponda . She is the Deputy Chief of Allergy and Immunology at Northwell Health in Great Neck, NY.
According to Ponda, it is common knowledge that the administration of "exposure therapy" through the mouth is more effective than methods such as the patch, but that risks of sudden anaphylactic reactions may increase with oral administration. She hopes that patch processing can still be an option.
"It is expected that this treatment will have a place in the future treatment of food allergy," said Ponda, "but the details of the dosage and the expected response rates will need to be clarified."
The study was funded by biopharmaceutical company DBV Technologies and was released on February 22 JAMA Network open now.
In an editorial accompanying the study, Dr. Jody Zylke, editor of the journal, said that "the theoretical benefits of this [patch] This approach includes ease of use and a reduced risk of allergic reactions. "
In fact, she noted that the tolerance of the patch was very high – 98.5% of patients used the treatment as indicated.
But Zylke added that the results of the new test are "not easy to interpret". Regardless of arguments based on statistics about the importance of new discoveries, doctors "will need to determine with patients whether a 35.3% response to the peanut patch is worthwhile," she said.
An experimental patch of peanut allergy is promising
Punita Ponda, MD, Assistant Chief, Division of Allergy and Immunology, Northwell Health, Great Neck, N.Y .; JAMA Network open nowFebruary 22, 2019
The American College of Allergy, Asthma & Immunology offers more information on peanut allergy.
Copyright © 2019 HealthDay. All rights reserved.
Quote:
A peanut allergy patch shows poor results in one trial (February 22, 2019)
recovered on February 22, 2019
from https://medicalxpress.com/news/2019-02-peanut-allergy-patch-middling-results.html
This document is subject to copyright. Apart from any fair use for study or private research purposes, no
part may be reproduced without written permission. Content is provided for information only.
[ad_2]
Source link
